Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 3/20 | 0.36 |
| ▸ | FLT1 | P17948 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817239 | 0.92 | SMN1; SMN2 (0.40) | KDRPDE1BCHEK1KCNH2 | |
| SCHEMBL4820147 | 0.88 | KDR (0.43) | KDRKITFLT1 | |
| SCHEMBL4816278 | 0.88 | KDR (0.43) | KDRKITFLT1 | |
| SCHEMBL17004678 | 0.87 | KDR (0.40) | KDRKITFLT1 | |
| SCHEMBL17004679 | 0.87 | KDR (0.40) | KDRKITFLT1 | |
| SCHEMBL17004684 | 0.86 | KDR (0.46) | KDRKITFLT1 | |
| SCHEMBL4889985 | 0.86 | CYP11B1 (0.42) | KDRKITFLT1KCNH2 | |
| SCHEMBL4817962 | 0.82 | HIF1A (0.33) | — | |
| SCHEMBL4815293 | 0.81 | SMN1; SMN2 (0.40) | KDRPDE1BCHEK1KCNH2 | |
| SCHEMBL4817411 | 0.81 | SMN1; SMN2 (0.40) | KDRPDE1BKITFLT1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | KDR 666/4885PDE1B 1081/4885KIT 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.